Doctor diagnosing a patient with neurological problems

...

Aristos Georgiou

By Aristos Georgiou

Science and Health Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


An analysis of cerebrospinal fluid has uncovered several proteins likely involved in the development and progression of Alzheimer's disease.

The study, published in the journal Nature Genetics, identified more than a dozen proteins that represent potential targets for future drug therapies designed to treat the disease, shedding light on how genetics and proteins influence the neurodegeneration seen in Alzheimer's.

"Genetic studies have identified genetic variants associated with Alzheimer's. But those studies do not identify, most of the time...the mechanism by which that gene leads to disease," Carlos Cruchaga, a professor of psychiatry and director of the NeuroGenomics and Informatics Center at Washington University School of Medicine, told Newsweek.

Read More on Science

"In order to address those problems, further studies are needed. Here, we integrated genetics with proteomics—which is the field that studies proteins at large scale—to identify the genes and proteins that are involved [in the] disease."

Alzheimer's disease is a progressive neurological disorder that causes brain cells to degenerate, leading to memory loss, cognitive decline, and behavioral changes. Over time, it can impair a person's ability to perform daily activities, recognize loved ones and communicate effectively, often resulting in a complete loss of independence.

Doctor diagnosing a patient with neurological problems

...

The disease is primarily characterized by the accumulation of two abnormal protein structures in the brain—amyloid-beta plaques and tau tangles—although their exact role in the disease process is still under investigation. In addition to amyloid-beta and tau, other proteins and molecular pathways are increasingly recognized as playing roles in Alzheimer's disease.

Alzheimer's is the most common form of dementia, the global societal cost of which is predicted to increase to $2 trillion by 2030, highlighting the pressing need to develop disease-modifying treatments.

While there is no cure for Alzheimer's disease, drug treatments aimed at slowing disease progression and alleviating symptoms are available, albeit with typically modest benefits. There have been some recent advances in targeting the underlying causes of the disease, although the long-term effectiveness and safety of these newer therapies remain to be fully determined.

Despite years of research, developing effective treatments for Alzheimer's has proved to be very challenging. The disease is complex, and many drug candidates have shown limited or no benefit in clinical trials, particularly in slowing or reversing cognitive decline. This high failure rate is partly due to the challenges in understanding the disease's exact causes and mechanisms and the difficulty of targeting it at the proper stages.

For the latest study, a team from WashU Medicine analyzed data from a large sample of people, including both healthy donors and people with Alzheimer's disease.

"My lab is the biobank for several studies. So we have, in fact, the cerebrospinal fluid (CSF) and blood collected for many Alzheimer's disease cases and controls in the lab," Cruchaga said. "We used the blood to extract DNA and generate the genetic data, and the CSF to generate the proteomic data."

CSF is a clear, colorless liquid surrounding the brain and spinal cord. In this study, it served as a valuable proxy for investigating the brain.

"For the analyses, we first identified what genetic variants regulate protein levels. And then, we analyzed if the same protein that modifies protein levels is also associated with Alzheimer's disease risk. After identifying the proteins implicated in Alzheimer's, we performed pathway analyses to determine the main biological processes that lead to disease."

The team identified 38 proteins likely to have a causal effect on the progression of Alzheimer's. According to Cruchaga, 15 of these are already targets of FDA-approved drugs that could be repositioned to treat the disease.

"The novelty and the strength of this analysis is that we have defined proteins that modify risk," Cruchaga said in a press release.

"Some other proteomic studies identify proteins associated with Alzheimer's disease, but many times, those proteins are simply associated with disease, not part of the causal pathways," he told Newsweek.

"In this study, by integrating genetics and proteomics, we were able to identify those proteins that are, in fact, part of the causal events that lead to disease. As we identified proteins that are part of the causal pathways and not just a secondary product of the disease, those proteins become potential targets for therapy."

Is there a health issue that's worrying you? Do you have a question about dementia? Let us know via health@newsweek.com. We can ask experts for advice, and your story could be featured on Newsweek.

Reference

Western, D., Timsina, J., Wang, L., Wang, C., Yang, C., Phillips, B., Wang, Y., Liu, M., Ali, M., Beric, A., Gorijala, P., Kohlfeld, P., Budde, J., Levey, A. I., Morris, J. C., Perrin, R. J., Ruiz, A., Marquié, M., Boada, M., . . . Cruchaga, C. (2024). Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease. Nature Genetics. https://doi.org/10.1038/s41588-024-01972-8

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines